New and emerging therapies for Parkinson disease

被引：16

作者：

Jankovic, J

机构：

[1] Baylor Coll Med, Parkinsons Dis Ctr, Houston, TX 77030 USA

[2] Baylor Coll Med, Movement Disorders Clin, Houston, TX 77030 USA

来源：

ARCHIVES OF NEUROLOGY | 1999年 / 56卷 / 07期

关键词：

D O I：

10.1001/archneur.56.7.785

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Few neurological disorders have been more successful in introducing novel therapies than Parkinson disease (PD), However, despite enormous progress, many challenges remain. Although levodopa is still the most effective drug in the symptomatic treatment of PD, adverse effects, particularly motor fluctuations and dyskinesias, limit its usefulness.(1) Furthermore, there is a growing concern about the escalating cost of PD treatment: the cost-benefit aspect of the novel approaches must be balanced against the advantages of long-term experience with established treatments.

引用

页码：785 / 790

页数：6

共 54 条

[41]

POLLAK P, 1998, PARKINSONS DIS MOVEM, P1085

[42] Tolcapone improves motor function in parkinsonian patients with the ''wearing-off'' phenomenon: A double-blind, placebo-controlled, multicenter trial [J].

Rajput, AH ;

Martin, W ;

SaintHilaire, MH ;

Dorflinger, E ;

Pedder, S .

NEUROLOGY, 1997, 49 (04) :1066-1071

[43] Cabergoline in the treatment of early Parkinson's disease: Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa [J].

Rinne, UK ;

Bracco, F ;

Chouza, C ;

Dupont, E ;

Gershanik, O ;

Masso, JFM ;

Montastruc, JL ;

Marsden, CD ;

Dubini, A ;

Orlando, N ;

Grimaldi, R ;

Bergamasco, B ;

Mamoli, A ;

Scarpa, M ;

Scarano, M ;

Canal, N ;

Franceschi, M ;

Albanese, A ;

Bentivoglio, AR ;

Barone, P ;

Cicarelli, G ;

Malesani, R ;

Micheli, F ;

Muchnik, S ;

Pliego, L ;

Somoza, M ;

Gori, HE ;

Dominguez, R ;

Famulari, A ;

Aljanati, R ;

Mikkelsen, B ;

Olive, JM ;

Burguera, J ;

Miquel, F ;

GimenezRoldan, S ;

Mateo, D ;

Allain, H ;

Verin, M ;

Degos, JD ;

Destee, A ;

Warter, JM ;

Bernardi, F ;

Chillotti, C ;

Serra, JP ;

Garriga, MC ;

Benecke, R ;

Pirotta, RMN ;

Grossoni, M .

NEUROLOGY, 1997, 48 (02) :363-368

[44] Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress [J].

Sawada, H ;

Ibi, M ;

Kihara, T ;

Urushitani, M ;

Akaike, A ;

Kimura, J ;

Shimohama, S .

ANNALS OF NEUROLOGY, 1998, 44 (01) :110-119

[45] Parkinson's disease - Improved function with GM1 ganglioside treatment in a randomized placebo-controlled study [J].

Schneider, JS ;

Roeltgen, DP ;

Mancall, EL ;

Chapas-Crilly, J ;

Rothblat, DS ;

Tatarian, GT .

NEUROLOGY, 1998, 50 (06) :1630-1636

[46] Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease [J].

Shannon, KM ;

Bennett, JP ;

Friedman, JH .

NEUROLOGY, 1997, 49 (03) :724-728

[47]

Shiosaki K, 1996, J PHARMACOL EXP THER, V276, P150

[48] DATATOP: A decade of neuroprotective inquiry [J].

Shoulson, I .

ANNALS OF NEUROLOGY, 1998, 44 (03) :S160-S166

[49] Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients [J].

Shults, CW ;

Beal, MF ;

Fontaine, D ;

Nakano, K ;

Haas, RH .

NEUROLOGY, 1998, 50 (03) :793-795

[50] Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models [J].

Steiner, JP ;

Hamilton, GS ;

Ross, DT ;

Valentine, HL ;

Guo, HZ ;

Connolly, MA ;

Liang, S ;

Ramsey, C ;

Li, JHJ ;

Huang, W ;

Howorth, P ;

Soni, R ;

Fuller, M ;

Sauer, H ;

Nowotnik, AC ;

Suzdak, PD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) :2019-2024

← 1 2 3 4 5 6 →